The present work represents a proof of concept for the successful application of multiplex and ultrasensitive molecular assessments of protein signatures and key immune targets, for example, PD‐L1, using minimal residual FNA materials of NSCLC lesions. This evidence concerns the gene CD274 and non-small cell lung carcinoma.